Viatris and Mapi Pharma Statement Regarding New Drug Application for GA Depot
Viatris Inc. has been informed that Mapi Pharma Ltd. has received a Complete Response Letter (CRL) regarding the New Drug…
‘You’re Fine.’ Why Delays in MS Diagnosis Matter.
by Lisa Doggett Family & lifestyle medicine physician, UT Health MS and Neuroimmunology Center; Sr. Medical Director, Sagility; Author of Up…
Stuart Schlossman
Tyruko Vs. Tysabri for Multiple Sclerosis Explained by Neurologist
Tyruko is a Tysabri biosimilar which has been FDA approved for multiple sclerosis. But is Tyruko just as good as…
Stuart Schlossman
Tyruko vs. Tysabri for Multiple Sclerosis: 5 Similarities and Differences to Know
Written by Cassandra Pardini, PharmD, MS | Reviewed by Daphne Berryhill, RPh – Key takeaways: The landscape of multiple sclerosis (MS) treatment options has evolved substantially over…
Stuart Schlossman
Will Frexalimab replace the anti-CD20s?
It is clear to me, and it should be clear to my colleagues, that anti-CD20 therapies have a limited shelf-life…
Stuart Schlossman
Press Release: Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS (sanofi.com)
Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS Paris, February 15, 2024. The…
Stuart Schlossman
Tysabri biosimilar Tyruko now available in Germany for RRMS
Tyruko (natalizumab), the first biosimilar of Tysabri, is now available in Germany for adults with highly active relapsing-remitting multiple sclerosis (RRMS). As a biosimilar, Tyruko has…
Stuart Schlossman
The MS Views and News Learning Channel, Presents: THE 2023 MS SYMPOSIUM – watch these educational videos with MS Neurologists Boster, Rosenthal, Steingo and more
PLAYING 2023 MS Symposium (Part 1 of 5) – LIVING WELL with MS, Pain Management, Biomarkers and More 40:26…
Stuart Schlossman
Sudo raises $116M to develop TYK2 inhibitors for MS, other diseases
Biopharmaceutical plans to advance 2 candidates into clinical trials in 2024 by Patricia Inacio, PhD | January 2, 2024 Sudo…
Stuart Schlossman
U.S. Neurologists Eagerly Await Promising Oral BTKis in MS Treatment Pipeline, Though Recent Trial Readouts Might Hamper Initial Excitement
Efficacy and safety of pipeline multiple sclerosis assets viewed as increasingly important characteristics, according to Spherix Global Insights. [Exton PA, December 13,…
Stuart Schlossman
